STOCK TITAN

AINOS INC SEC Filings

AIMDW NASDAQ

Welcome to our dedicated page for AINOS SEC filings (Ticker: AIMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Searching Ainos Inc’s SEC archive for clues about progress in its AI-powered point-of-care tests or low-dose interferon trials quickly turns into a maze of biotech jargon and cross-referenced exhibits. Stock Titan brings Ainos Inc SEC filings explained simply: every 8-K material events explained, every exhibit summarized by AI, and critical trial milestones surfaced in seconds.

Need the latest Ainos Inc quarterly earnings report 10-Q filing? The moment it posts to EDGAR, we publish it with AI commentary that highlights R&D spend, cash runway, and VELDONA development costs. Ainos Inc Form 4 insider transactions real-time appear instantly, so you can track executive stock moves alongside our AI-driven sentiment notes. You’ll also find the Ainos Inc annual report 10-K simplified, the Ainos Inc proxy statement executive compensation sections clarified, and an at-a-glance dashboard for Ainos Inc earnings report filing analysis.

Investors often scan Ainos Inc insider trading Form 4 transactions for signals around clinical readouts, compare manufacturing head-count in the 10-K to POCT rollout plans, or watch liquidity metrics inside the 10-Q. Stock Titan connects those dots for you:

  • AI keyword search across all filings for faster discovery
  • Side-by-side quarter comparisons that make understanding Ainos Inc SEC documents with AI effortless
  • Push alerts for Ainos Inc executive stock transactions Form 4
  • Contextual notes on each Ainos Inc 8-K material events explained

Skip the PDFs and keep your focus on decisions, not document hunting.

Rhea-AI Summary

Ainos, Inc. (AIMD) – Form 4 insider filing

Director Ting-Chuan Lee disclosed the sale of 2,894 common shares on 25 June 2025 at $0.51 per share. The filing specifies the transaction was undertaken to satisfy income-tax obligations. After the sale, Lee continues to hold 1,428,538 shares directly. No derivative securities were involved and no other changes in beneficial ownership were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

On 25 June 2025, Taiwan Carbon Nano Technology Corporation (TCNT) – a >10 % beneficial owner of Ainos, Inc. (AIMD) – filed a Form 4 disclosing a single disposition of issuer common stock executed on 23 June 2025.

  • Shares involved: 29,476 AIMD common shares were transferred under transaction code “S.” No unit price was reported because the move was part of a share-exchange agreement, not a market sale.
  • Post-transaction stake: TCNT continues to own 5,470,524 AIMD shares directly, maintaining its 10 %-plus ownership position.
  • Rationale: Footnote (1) explains the shares were exchanged with ASE Test, Inc. for 5,687,109 ordinary shares of Ainos Inc. (Cayman). The filing therefore appears to reflect an internal restructuring rather than a liquidity-driven sell-down.
  • Other securities: The filing reports no derivative securities acquired or disposed of, and there are no option exercises.

Given the small size of the exchange relative to TCNT’s remaining holdings and the absence of pricing data, the event is viewed as administrative and non-material for existing shareholders. No strategic shift or insider selling trend is evident.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

ASE Test Inc, a 10% owner of Ainos Inc (AIMD), reported a significant insider transaction on June 23, 2025. The company acquired 29,476 shares of common stock through a Share Exchange Agreement with Taiwan Carbon Nano Technology Corporation.

Key transaction details:

  • Acquired shares in exchange for 5,687,109 ordinary shares of Ainos Inc. (Cayman Islands)
  • Exchange value approximately $0.497 per share
  • Total beneficial ownership following transaction: 58,887 shares
  • Ownership form: Direct through ASE Test, indirect through ASE Technology Holding Co., Ltd

This Form 4 filing indicates a strategic share exchange transaction that increases ASE Test's stake in Ainos Inc. The transaction was executed through a formal agreement dated June 3, 2025, demonstrating continued institutional investment interest in the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Ainos announced a strategic partnership with Kenmec Mechanical Engineering through an 8-K filing dated June 24, 2025. The company, listed on the Nasdaq Stock Market under symbols AIMD (common stock) and AIMDW (warrants), made this material disclosure in accordance with SEC regulations.

Key details from the filing:

  • The partnership agreement is legally binding, though specific terms were not disclosed in the 8-K
  • The announcement was made via press release, included as Exhibit 99.1
  • The filing was signed by CEO Chun-Hsien Tsai
  • Company headquarters: 8880 Rio San Diego Drive, San Diego, CA

This strategic alliance could represent a significant business development for Ainos, potentially impacting its operational capabilities and market position, though investors should refer to the full press release for detailed partnership terms and implications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Director Chun-Jung Tsai of Ainos reported multiple sales of common stock in June 2025:

  • June 18: Sold 5,000 shares at $0.5217 per share
  • June 19: Sold 10,903 shares at $0.5517 per share
  • June 23: Sold 10,000 shares at $0.50 per share

Following these transactions, Tsai directly owns 1,401,997 shares of common stock, representing a reduction of 25,903 shares from their previous position. The sales occurred at prices ranging from $0.50 to $0.5517 per share, with a total value of approximately $13,900. These insider sales may indicate the director's personal portfolio management decisions or views on the company's valuation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of AINOS (AIMDW)?

The current stock price of AINOS (AIMDW) is $0.15 as of June 26, 2025.

What are the core business areas of Ainos Inc?

Ainos Inc focuses on developing AI-powered point-of-care testing solutions and low-dose interferon therapeutics. Their innovations address unmet medical needs in human and veterinary health, leveraging advanced biotechnology and AI technologies.

How does Ainos Inc utilize AI in its operations?

The company employs its proprietary AI Nose technology to digitize the sense of smell, enable the detection of volatile organic compounds, and power telehealth-friendly diagnostic solutions. This technology is also being applied in industrial safety and robotics.

What products are included in Ainos Inc's portfolio?

Ainos Inc's portfolio includes VELDONA human therapeutics, VELDONA veterinary supplements, and innovative POCT solutions integrated with AI-powered sensors, along with its groundbreaking AI Nose platform.

In which medical conditions is Ainos Inc focusing its therapeutic development?

Their therapeutic development centers on conditions such as influenza, hepatitis C, thrombocytopenia, Sjögren's syndrome, and HIV-related oral warts, utilizing a unique low-dose oral interferon approach.

What is the significance of the AI Nose technology?

AI Nose technology is significant for its ability to digitize olfactory sensing, enabling rapid and non-invasive diagnostics in healthcare. It also finds applications in smart manufacturing, robotics, and environmental monitoring.

How does the company position itself within the competitive landscape?

Ainos Inc differentiates itself through a diversified product pipeline, strong intellectual property in innovative diagnostics and therapeutics, and strategic partnerships that enhance technological and clinical capabilities.

What strategic advantages support Ainos Inc's business model?

Their business model is supported by a robust R&D foundation, rigorous clinical research, strategic collaborations for technology licensing, and a diversified approach that bridges human and veterinary health markets.

How does Ainos Inc ensure the credibility of its innovations?

The company applies stringent clinical testing, adheres to Good Clinical Practice standards, and secures broad patent protection. This fosters trust through demonstrable expertise, industry validation, and a commitment to transparent research.
AINOS INC

NASDAQ:AIMDW

AIMDW Rankings

AIMDW Stock Data

17.22M
Medical Devices
Pharmaceutical Preparations
Link
United States
SAN DIEGO